Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lisa Pennington

Physician Assistant, Medical Flatwoods, KY Physician Assistant

NPI 1710968557 CMS profile 11210416

2420 Argillite Rd Ste B, Flatwoods, KY 41139

Open in the dashboard

General payments

$7,237

469 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lisa Pennington of Flatwoods, KY is reported in the CMS Open Payments database as having received $7,237 across 469 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,239 133
2024 General $1,665 103
2023 General $1,437 96
2022 General $944 69
2021 General $953 68

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lisa Pennington
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Lisa Pennington were reported at $2,239. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Lisa Pennington Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $953 $156 $41–$563 $132
2022 $944 $185 $55–$649 $149
2023 $1,437 $199 $58–$717 $160
2024 $1,665 $206 $62–$740 $164
2025 $2,239 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,320 88 payments
  2. GlaxoSmithKline, LLC. $1,062 80 payments
  3. Pfizer Inc. $865 60 payments
  4. Lilly USA, LLC $728 49 payments
  5. Novo Nordisk Inc $651 38 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $499 32 payments
  7. AstraZeneca Pharmaceuticals LP $384 22 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $298 20 payments
  9. Amgen Inc. $156 6 payments
  10. Abbott Laboratories $144 8 payments
  11. Other $1,130 66 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,237 469 payments
Products named General payments · program years 2021–2025
  1. TRELEGY ELLIPTA $1,052 79 payments
  2. NURTEC ODT $781 55 payments
  3. VRAYLAR $539 36 payments
  4. MOUNJARO $505 32 payments
  5. XIFAXAN $499 32 payments
  6. RYBELSUS $491 28 payments
  7. Ozempic $430 24 payments
  8. ELIQUIS $421 28 payments
  9. UBRELVY $388 30 payments
  10. QULIPTA $357 24 payments
  11. Other $4,116 255 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 123 drugs

Part D claims

7,043

Median for Physician Assistant: 241

Drug cost

$695,832

Median for Physician Assistant: $4,110

Branded share of claims

17.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 104 $128,290
Jardiance Empagliflozin Brand 94 $117,439
Mounjaro Tirzepatide Brand 77 $86,862
Januvia Sitagliptin Phosphate Brand 45 $61,788
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 54 $55,570
Eliquis Apixaban Brand 48 $55,517
Trulicity Dulaglutide Brand 24 $30,623
Vraylar Cariprazine Hcl Brand 12 $17,001
Xarelto Rivaroxaban Brand 18 $16,387
Myrbetriq Mirabegron Brand 16 $13,244

The 10 drugs with the highest cost, of 123 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$44,232

Of which drugs: $6,093

Medicare patients

186

Average age 70

Services billed

1,023

111 women, 75 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Diabetes 33%
COPD 31%
Ischemic heart disease 30%
Depression 21%
Chronic kidney disease 20%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscov2 vac 50 mcg/0.5ml im 91322 Office 14 14 $2,187

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $213
$213 54 —
VRAYLAR
  • AbbVie, Inc. $191
$191 12 —
MOUNJARO
  • Lilly USA, LLC $188
$188 77 —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $143
$143 — —
NURTEC ODT
  • PFIZER INC. $112
$112 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

469 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record